Wolf dieter busse (27 risultati)

Broschiert. Condizione: Gut. 132 Seiten Das Buch befindet sich in einem ordentlich erhaltenen Zustand. Leichte altersbedingte Anbräunung des Papiers. In ENGLISCHER Sprache. Sprache: Englisch Gewicht in Gramm: 260.

Heft. Condizione: Gut. 35 Seiten; illustriert; Der Erhaltungszustand des hier angebotenen Werks ist trotz seiner Bibliotheksnutzung sehr sauber. Es befindet sich neben dem Rückenschild lediglich ein Bibliotheksstempel im Heft; ordnungsgemäß entwidmet. Neben dem oben aufgeführten Aufsatz befinden sich auch weitere Beiträge auch anderer Autoren in dem Werk. Sprache: Deutsch Gewicht in Gramm: 50.…

Hardcover. Condizione: Fine. Vergilbt / ausgeblichen.

Hardcover. Condizione: Fine. Leichte Kratzer / Abnutzungen / Druckstellen; Abnutzung / Risse - leicht; Vergilbt / ausgeblichen.

Condizione: gut. 130 S., 21 cm, Bibliotheksexemplar, Aufkleber, Rücken mit Klebestreifen verstärkt, Dreieckstasche. DV: Zahn Sprache: Deutsch.

15 x 23 cm. 129 pages. Paperback. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, daher Mängelexemplar gestempelt, sonst sehr guter Zustand. Imperfect copy due to slightly bumped cover, apart from this in very good condition. Stamped. Sprache: Englisch.

Condizione: New. In.

Condizione: New. In.

Condizione: New. pp. xii + 117.

Condizione: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | At the workshop held in Leverkusen on December 1, 1993, Professor Dr. Stanislav Kazda was honored on the occasion of his retirement for his scientific contributions and his involvement in drug development in our company, Bayer AG. In a recent article by Eugene Garfield (Current ContentslLife Sciences 36:3-15, 1993), what most of us participating in this workshop have supposed for years was confirmed: that Kazda is one of the leading scientific authors in academia worldwide. In the said survey of citations of biomedical research articles, Kazda is number 29 in terms of actual impact, individual ~itations, and total number of published manuscripts (and this only covers the time period from 1981 to 1992). In addition, his work has contributed significantly to the number eight ranking of our company in the so-called Corporation List. With the support of colleagues inside and outside the company, Kazda made a new substance class, the 1, 4-dihydropyridines, discovered by Bossert and Vater, well known to the scientific community on a worldwide basis and established its outstanding usefulness in hypertension. He has contributed numerous publi­ cations on the pharmacology of these calcium antagonists and organized several international conferences on the topic. Although he became famous as a cardiovascular pharmacologist, he started his career as a physician with the subjects obstetrics and gynecology. He studied at the Medical Faculty in Prague and at the Universities of Kasan and Kharkow (1950-1957).…

Condizione: New. pp. xi + 119.

Paperback. Condizione: Brand New. illustrated edition. 129 pages. 9.25x6.10x0.31 inches. In Stock.

Paperback. Condizione: Brand New. 1st edition. 130 pages. 9.25x6.10x0.32 inches. In Stock.

Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - At the workshop held in Leverkusen on December 1, 1993, Professor Dr. Stanislav Kazda was honored on the occasion of his retirement for his scientific contributions and his involvement in drug development in our company, Bayer AG. In a recent article by Eugene Garfield (Current ContentslLife Sciences 36:3-15, 1993), what most of us participating in this workshop have supposed for years was confirmed: that Kazda is one of the leading scientific authors in academia worldwide. In the said survey of citations of biomedical research articles, Kazda is number 29 in terms of actual impact, individual ~itations, and total number of published manuscripts (and this only covers the time period from 1981 to 1992). In addition, his work has contributed significantly to the number eight ranking of our company in the so-called Corporation List. With the support of colleagues inside and outside the company, Kazda made a new substance class, the 1, 4-dihydropyridines, discovered by Bossert and Vater, well known to the scientific community on a worldwide basis and established its outstanding usefulness in hypertension. He has contributed numerous publi cations on the pharmacology of these calcium antagonists and organized several international conferences on the topic. Although he became famous as a cardiovascular pharmacologist, he started his career as a physician with the subjects obstetrics and gynecology. He studied at the Medical Faculty in Prague and at the Universities of Kasan and Kharkow (1950-1957).…

Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - At the Pharmacology Workshop held in Wuppertal on December 11, 1992, Dr. Alexander Scriabine was honored for his contribution to drug develop ment at our company. Dr. Scriabine was the first pharmacologist to join Miles in West Haven, CT, in 1979. He established the Miles Institute for Preclinical Pharmacology, at the Yale campus, which was devoted to cardiovascular, metabolic and, 2 later, CNS research. At that time Ca + antagonists were not yet available in the USA, but well established in Europe. At Bayer, Bossert and Vater discovered 1,4-dihydropyridines in the late 1960s, and Fleckenstein identified 2 nifedipine as the most potent Ca + antagonist available at that time. This 2 discovery led to the establishment of Ca + antagonists as leading cardio vascular drugs throughout the world and to the marketing of nifedipine as Adalat by Bayer. The main function of the Miles Institute for Preclinical 2 Pharmacology was the introduction of Bayer Ca + antagonists to the American scientific community. Scriabine, in collaboration with Stanislav Kazda and Bernward Garthoff, contributed numerous publications on the 2 pharmacology of Bayer Ca + antagonists, supported many collaborative studies with extramural investigators in the USA, and organized several 2 international conferences on Ca + antagonists. These conferences contri buted to the recognition of the importance of these drugs for the treatment of hypertension and coronary heart disease in North America.…

Perfect Paperback. Condizione: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -At the workshop held in Leverkusen on December 1, 1993, Professor Dr. Stanislav Kazda was honored on the occasion of his retirement for his scientific contributions and his involvement in drug development in our company, Bayer AG. In a recent article by Eugene Garfield (Current ContentslLife Sciences 36:3-15, 1993), what most of us participating in this workshop have supposed for years was confirmed: that Kazda is one of the leading scientific authors in academia worldwide. In the said survey of citations of biomedical research articles, Kazda is number 29 in terms of actual impact, individual ~itations, and total number of published manuscripts (and this only covers the time period from 1981 to 1992). In addition, his work has contributed significantly to the number eight ranking of our company in the so-called Corporation List. With the support of colleagues inside and outside the company, Kazda made a new substance class, the 1, 4-dihydropyridines, discovered by Bossert and Vater, well known to the scientific community on a worldwide basis and established its outstanding usefulness in hypertension. He has contributed numerous publi cations on the pharmacology of these calcium antagonists and organized several international conferences on the topic. Although he became famous as a cardiovascular pharmacologist, he started his career as a physician with the subjects obstetrics and gynecology. He studied at the Medical Faculty in Prague and at the Universities of Kasan and Kharkow (1950-1957). 132 pp. Englisch.…

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -At the Pharmacology Workshop held in Wuppertal on December 11, 1992, Dr. Alexander Scriabine was honored for his contribution to drug develop ment at our company. Dr. Scriabine was the first pharmacologist to join Miles in West Haven, CT, in 1979. He established the Miles Institute for Preclinical Pharmacology, at the Yale campus, which was devoted to cardiovascular, metabolic and, 2 later, CNS research. At that time Ca + antagonists were not yet available in the USA, but well established in Europe. At Bayer, Bossert and Vater discovered 1,4-dihydropyridines in the late 1960s, and Fleckenstein identified 2 nifedipine as the most potent Ca + antagonist available at that time. This 2 discovery led to the establishment of Ca + antagonists as leading cardio vascular drugs throughout the world and to the marketing of nifedipine as Adalat by Bayer. The main function of the Miles Institute for Preclinical 2 Pharmacology was the introduction of Bayer Ca + antagonists to the American scientific community. Scriabine, in collaboration with Stanislav Kazda and Bernward Garthoff, contributed numerous publications on the 2 pharmacology of Bayer Ca + antagonists, supported many collaborative studies with extramural investigators in the USA, and organized several 2 international conferences on Ca + antagonists. These conferences contri buted to the recognition of the importance of these drugs for the treatment of hypertension and coronary heart disease in North America. 136 pp. Englisch.…

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. At the workshop held in Leverkusen on December 1, 1993, Professor Dr. Stanislav Kazda was honored on the occasion of his retirement for his scientific contributions and his involvement in drug development in our company, Bayer AG. In a recent article by Eug.…

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Twenty Years of Dihydropyridines.- 1,4-Dihydropyridines and the 1,4-Dihydropyridine Receptor.- 1,4-Dihydropyridines: Effects of Chirality and Conformation on Their Activity.- Pharmacological Classification of High-Threshold Calcium Channels in Rat Neurons.-. …

Condizione: New. Print on Demand pp. xii + 117 42 Figures.

Condizione: New. PRINT ON DEMAND pp. xii + 117.

Condizione: New. Print on Demand pp. xi + 119 53 Figures.

Taschenbuch. Condizione: Neu. Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond | Bernward Garthoff (u. a.) | Taschenbuch | xii | Englisch | 1995 | Springer-Verlag GmbH | EAN 9783540585459 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.…

Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -At the Pharmacology Workshop held in Wuppertal on December 11, 1992, Dr. Alexander Scriabine was honored for his contribution to drug develop ment at our company. Dr. Scriabine was the first pharmacologist to join Miles in West Haven, CT, in 1979. He established the Miles Institute for Preclinical Pharmacology, at the Yale campus, which was devoted to cardiovascular, metabolic and, 2 later, CNS research. At that time Ca + antagonists were not yet available in the USA, but well established in Europe. At Bayer, Bossert and Vater discovered 1,4-dihydropyridines in the late 1960s, and Fleckenstein identified 2 nifedipine as the most potent Ca + antagonist available at that time. This 2 discovery led to the establishment of Ca + antagonists as leading cardio vascular drugs throughout the world and to the marketing of nifedipine as Adalat by Bayer. The main function of the Miles Institute for Preclinical 2 Pharmacology was the introduction of Bayer Ca + antagonists to the American scientific community. Scriabine, in collaboration with Stanislav Kazda and Bernward Garthoff, contributed numerous publications on the 2 pharmacology of Bayer Ca + antagonists, supported many collaborative studies with extramural investigators in the USA, and organized several 2 international conferences on Ca + antagonists. These conferences contri buted to the recognition of the importance of these drugs for the treatment of hypertension and coronary heart disease in North America.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 136 pp. Englisch.…

Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -At the workshop held in Leverkusen on December 1, 1993, Professor Dr. Stanislav Kazda was honored on the occasion of his retirement for his scientific contributions and his involvement in drug development in our company, Bayer AG. In a recent article by Eugene Garfield (Current ContentslLife Sciences 36:3-15, 1993), what most of us participating in this workshop have supposed for years was confirmed: that Kazda is one of the leading scientific authors in academia worldwide. In the said survey of citations of biomedical research articles, Kazda is number 29 in terms of actual impact, individual ~itations, and total number of published manuscripts (and this only covers the time period from 1981 to 1992). In addition, his work has contributed significantly to the number eight ranking of our company in the so-called Corporation List. With the support of colleagues inside and outside the company, Kazda made a new substance class, the 1, 4-dihydropyridines, discovered by Bossert and Vater, well known to the scientific community on a worldwide basis and established its outstanding usefulness in hypertension. He has contributed numerous publi cations on the pharmacology of these calcium antagonists and organized several international conferences on the topic. Although he became famous as a cardiovascular pharmacologist, he started his career as a physician with the subjects obstetrics and gynecology. He studied at the Medical Faculty in Prague and at the Universities of Kasan and Kharkow (1950-1957).Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 132 pp. Englisch.…

Condizione: New. PRINT ON DEMAND pp. xi + 119.